title: Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
authors.affiliation: Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
authors.forename: A
authors.initials: A
authors.lastname: Chanan-Khan
authors.affiliation: Department of Internal Medicine, Kaposi Mor Oktato Korhaz, Kaposvar, Hungary.
authors.forename: M
authors.initials: M
authors.lastname: Egyed
authors.affiliation: Department of Hematology, Medical University of Lodz, Lodz, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Robak
authors.affiliation: Department of Oncology, Hospital Erasto Gaertner, Curitiba, Brazil.
authors.forename: F A
authors.initials: FA
authors.lastname: Martinelli de Oliveira
authors.affiliation: Hematology Service, Hospital Universitario Donostia, San Sebastian, Spain.
authors.forename: M A
authors.initials: MA
authors.lastname: Echeveste
authors.affiliation: Division of Hematology, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Dolan
authors.affiliation: Department of Hematology, Hospital Charles LeMoyne, Greenfield Park, Quebec, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Desjardins
authors.affiliation: Department of Hematology, Medical University of Lodz, Lodz, Poland.
authors.forename: J Z
authors.initials: JZ
authors.lastname: Blonski
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: J
authors.initials: J
authors.lastname: Mei
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: N
authors.initials: N
authors.lastname: Golany
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Centre for Haemato-Oncology, Barts Cancer Institute, London, UK.
authors.forename: J G
authors.initials: JG
authors.lastname: Gribben
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D002699:Chlorambucil; D013792:Thalidomide; D000077269:Lenalidomide